5.3 Asthma: Diagnosis, Stepwise Therapy & Status Asthmaticus

1. Asthma: Diagnosis & GINA 2024 Guidelines

Asthma is a chronic inflammatory disorder of the conducting airways characterized by bronchial hyperresponsiveness and variable, reversible airflow limitation.

Objective Diagnostic Criteria

• Reversible Airflow Limitation on Spirometry: A post-bronchodilator increase in FEV1 of > 12% AND > 200 mL compared with baseline pre-bronchodilator FEV1 (measured 10–15 minutes after 200–400 mcg albuterol).
• Bronchoprovocation Testing (Methacholine Challenge): Used when asthma is clinically suspected but baseline spirometry is normal. A PC20 (provocative concentration causing a >=20% fall in FEV1) <= 8 mg/mL confirms airway hyperresponsiveness (high negative predictive value; if negative, asthma is virtually excluded).
• Fractional Exhaled Nitric Oxide (FeNO): FeNO > 50 ppb in adults correlates with active Type 2 eosinophilic airway inflammation and predicts positive responsiveness to inhaled corticosteroids.

GINA 2024 Management Tracks

GINA divides asthma management into two primary tracks. Track 1 is the preferred strategy across all severity steps because it substantially reduces the risk of severe exacerbations and asthma-related mortality compared with traditional SABA-only relief.

• Track 1: Preferred Strategy (Anti-Inflammatory Reliever / SMART):
  • The reliever is low-dose ICS-formoterol taken as needed across all steps.
  • Mechanism: Formoterol is a long-acting beta-2 agonist (LABA) with an onset of action as rapid as albuterol (1–3 minutes) combined with a 12-hour duration of action. Co-administering low-dose budesonide (or beclomethasone) whenever the patient experiences symptoms delivers an immediate burst of anti-inflammatory therapy at the earliest onset of an exacerbation.
  • Step 1 & 2: Low-dose ICS-formoterol as needed only for symptom relief (no daily scheduled controller).
  • Step 3: Low-dose maintenance ICS-formoterol (1 inhalation daily or BID) + low-dose ICS-formoterol as needed for relief (Single Maintenance and Reliever Therapy — SMART / MART).
  • Step 4: Medium-dose maintenance ICS-formoterol (2 inhalations BID) + low-dose ICS-formoterol as needed for relief.
  • Step 5: High-dose maintenance ICS-formoterol + add-on LAMA (Tiotropium Respimat 2.5 mcg daily) + phenotypic evaluation for biologic therapy.
• Track 2: Alternative Strategy: Regular daily ICS (or ICS-LABA) maintenance with as-needed SABA (Albuterol) reliever. (Requires verified adherence to daily controller before prescribing SABA).

Add-On Biologic Therapies for Severe Uncontrolled Asthma (Step 5)

2. Severe Acute Asthma Exacerbation (Status Asthmaticus)

Acute Resuscitation Protocol

1. High-Dose Inhaled Bronchodilators: Albuterol 2.5–5 mg plus Ipratropium bromide 0.5 mg via nebulizer every 20 minutes for 3 doses, or continuous nebulized albuterol (10–15 mg/hour).
2. Systemic Corticosteroids: Early administration is critical. Oral Prednisone 40–60 mg or IV Methylprednisolone 60–125 mg. Corticosteroids take 4–6 hours to exert clinical genomic anti-inflammatory effects.
3. Intravenous Magnesium Sulfate: 2 g IV infusion over 20 minutes. Indicated for severe exacerbations with persistent hypoxemia, FEV1 < 40% predicted, or lack of response after 1 hour of intensive bronchodilator therapy. Acts via calcium channel antagonism on bronchial smooth muscle causing smooth muscle relaxation.
4. Controlled Oxygen Therapy: Target SaO2 93–95% in adults (94–98% in pregnant women). Hyperoxia should be avoided to prevent V/Q mismatch worsening and hypercapnia.
5. Contraindicated Medications: Sedatives, anxiolytics, and hypnotics are strictly contraindicated during acute asthma exacerbations; their respiratory depressant effects precipitate hypercapnic respiratory arrest.

Warning Signs of Impending Respiratory Failure

• The "Normal" PaCO2 Paradox: Patients in severe asthma exacerbations hyperventilate due to hypoxemia and bronchospasm, resulting in respiratory alkalosis (PaCO2 < 35 mmHg). A normal (40–42 mmHg) or elevated (>45 mmHg) PaCO2 in a visibly tachypneic patient indicates severe respiratory muscle exhaustion, diaphragm fatigue, and impending catastrophic respiratory arrest.
• Additional Red Flags: Silent chest on auscultation (insufficient airflow to generate wheezes), diaphoresis, pulsus paradoxus > 20 mmHg, altered mental status (confusion, lethargy), bradycardia, and refractory hypoxemia.
• Management of Impending Respiratory Failure: Immediate transfer to the Intensive Care Unit, preparation for rapid sequence intubation (RSI) using ketamine (bronchodilatory properties) and succinylcholine/rocuronium, and mechanical ventilation with low respiratory rate, prolonged expiratory time (I:E ratio 1:3 to 1:4), and low tidal volume (6 mL/kg PBW) to avoid dynamic hyperinflation and tension pneumothorax / auto-PEEP.